Introduction {#section5-1758835919833863}
============

Nasopharyngeal carcinoma (NPC) is endemic in Southeast Asia, where the incidence rate ranges 15--50 cases per 100,000 people.^[@bibr1-1758835919833863],[@bibr2-1758835919833863]^ Presently, the primary treatment modality for NPC is radiotherapy (RT). With advancements in RT technology and imaging techniques, the locoregional control rate is higher than 90%, and the main failure pattern is distant metastasis.^[@bibr3-1758835919833863],[@bibr4-1758835919833863]^ Patients with NPC are divided into N0--N3 categories, based on the American Joint Commission on Cancer (AJCC) classification.^[@bibr5-1758835919833863]^ Recent evidence^[@bibr6-1758835919833863]^ has indicated that more than 75% of distant failures are concentrated in the advanced N-stage (stage N2--N3). Since outcomes are particularly poor for NPC patients with distant metastasis, with a median overall survival (OS) ranging from 7 to 16 months,^[@bibr7-1758835919833863][@bibr8-1758835919833863]--[@bibr9-1758835919833863]^ identifying patients with a high risk of metastasis is important for tailoring individualized therapy and reducing distant metastasis.

Currently, the standard treatment for locoregionally advanced NPC is concurrent chemoradiotherapy (CCRT).^[@bibr10-1758835919833863][@bibr11-1758835919833863]--[@bibr12-1758835919833863]^ However, CCRT alone may not be sufficient for some patients, particularly those with high-risk distant metastasis.^[@bibr13-1758835919833863]^ Although the addition of adjuvant chemotherapy (AC) to CCRT might reduce distant metastasis for NPC patients at an elevated distant failure risk, the concurrent--adjuvant approach has low compliance for three cycles of AC (around 60%).^[@bibr14-1758835919833863]^ Induction chemotherapy (IC) offers advantages for improved tolerance and early eradication of micrometastases compared with AC.^[@bibr14-1758835919833863],[@bibr15-1758835919833863]^ A recent phase III trial by Sun and colleagues reported that IC plus CCRT could improve distant metastasis-free survival (DMFS) in locoregionally advanced NPC compared with CCRT alone.^[@bibr15-1758835919833863]^ However, another trial by Fountzilas and colleagues^[@bibr16-1758835919833863]^ did not observe significant survival improvements. Hence, it remains unclear whether all advanced N-stage NPC patients would benefit from the addition of IC to CCRT.

To fill the current gaps in knowledge, we conceived and initiated a large-scale, real-world study to establish a nomogram model with improved prediction accuracy compared with clinical risk factors for distant metastasis in advanced N-stage NPC. We then applied this nomogram to place patients into risk groups (low, intermediate, and high risk). Additionally, individual comparisons of CCRT plus IC and CCRT alone were performed for each well-matched group based on a propensity score matching method to assess the benefit of IC in advanced N-stage NPC patients.

Materials and methods {#section6-1758835919833863}
=====================

Study population {#section7-1758835919833863}
----------------

This study utilized the NPC-specific database, which is derived from Sun Yat-sen University Cancer Center's (SYSUCC) well-established big data intelligence platform. A total of 10,126 patients were identified with histologically proven nondisseminated NPC, diagnosed from April 2009 to December 2015. Patients demographic, diagnostic, and therapeutic information were obtained from the intelligence platform using keywords such as 'diagnosis', 'histologic type', 'age at first diagnosis', 'sex', 'disease stage', 'RT technology', and 'Epstein--Barr virus (EBV) DNA'. Detailed descriptions of the SYSUCC intelligence platform have previously been published.^[@bibr17-1758835919833863]^ Briefly, this novel 'big data' research system, enables organizing, integrating, restructuring, and updating data in real-time from numerous clinical business systems, based on a well-designed data model and algorithm.

In this study, we identified eligible patients based on the following inclusion criteria: pathologically diagnosed NPC; no evidence of distant metastasis; N2--3 disease based on the AJCC staging system (8th edition, 2016)^[@bibr5-1758835919833863]^; treated with intensity-modulated radiotherapy (IMRT); complete medical history; and baseline laboratory testing, including plasma EBV DNA, high-sensitivity C-reactive protein (hs-CRP), hemoglobin (HGB), and lactate dehydrogenase (LDH). Clinical information on the 3089 patients that met the inclusion criteria were included. The present study received approval from the Institutional Review Board (IRB-approved number, YB2018-005) of SYSUCC, Guangzhou, China. Written informed consent for the use of clinical data and collected samples for future studies (including retrospective studies) were obtained when the patients were admitted to receive treatment as a general standard procedure for patients treated in our center. All patient records were anonymous and de-identified before the analysis.

Diagnosis and treatment {#section8-1758835919833863}
-----------------------

All patients underwent complete evaluation before treatment, including a physical examination, fiberoptic nasopharyngoscopy, hematology and biochemistry profiling, magnetic resonance imaging (MRI) scanning of the suprasellar cistern to the collarbone, computed tomography (CT), abdominal ultrasonography, whole body bone scan (ECT), or 18F-fluorodeoxyglucose positron emission tomography (PET) and CT (PET-CT). Real-time quantitative polymerase chain reaction was used to measure plasma EBV DNA concentrations as described in prior studies.^[@bibr18-1758835919833863],[@bibr19-1758835919833863]^ The two radiation oncologists specializing in head and neck cancer restaged patients.^[@bibr5-1758835919833863]^ Patients were treated according to treatment principles for NPC established by SYSCC (see [supplementary material](https://journals.sagepub.com/doi/suppl/10.1177/1758835919833863)).

Data sharing {#section9-1758835919833863}
============

Key raw data were uploaded onto the Research Data Deposit public platform (RDD), with the approval number of RDDB2018000430.

Follow up and end points {#section10-1758835919833863}
------------------------

Patients were examined during the first 2 years at least every 3 months, and every 6 months for 3 years thereafter. During the visits, clinical examinations, fiberoptic nasopharyngoscopy, and plasma EBV DNA were routinely performed. Patients with a clinical suspicion of metastasis were recommended for MRI, abdominal sonography, ECT, or PET-CT, followed by confirmatory cytological biopsies if possible. The study's primary endpoint was DMFS, and the secondary endpoint was OS. We calculated DMFS as the time from the date of initial treatment on day 1 to the first distant relapse date; and OS to all-cause mortality, or the last follow-up visit date, whichever occurred first.

Statistical analysis {#section11-1758835919833863}
--------------------

We converted continuous variables to categorical variables according to clinical cut-off points (HGB, LDH, hs-CRP) or as determined by prior study findings (age, plasma EBV DNA).^[@bibr20-1758835919833863][@bibr21-1758835919833863][@bibr22-1758835919833863]--[@bibr23-1758835919833863]^ The Kaplan--Meier method was used to calculate survival rates which were compared using log-rank tests.^[@bibr24-1758835919833863]^ Potential factors were analyzed with univariate and multivariate Cox proportional hazards models. Variables with *p* \< 0.05 in the univariate analyses were included in the multivariable Cox regression analyses. Additionally, forest plots were generated to present adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) of the validated predictors for DMFS and OS.

Based on the multivariable Cox regression analysis, nomograms were generated. The selection of the final prediction model was performed using a backward step-down selection process with the Akaike information criterion.^[@bibr25-1758835919833863]^ Nomogram performance was assessed using the concordance index (c-index) and evaluated through means of comparison of nomogram-predicted and observed Kaplan--Meier estimates of survival probability. Additionally, bootstraps with 1000 resamples were applied.

We scored the risk of distant metastasis for all patients with the aim of categorizing patients into groups (low, intermediate, and high risk) according to the prognostic factors in the nomogram for DMFS. We identified patients that would benefit most from CCRT with IC by performing individual comparisons of IC plus CCRT *versus* CCRT alone for each risk group. To reduce the effect of potential confounders on selection bias, the propensity score matching (PSM) method without replacement was performed for comparisons using the nearest-neighbor method with a stringent caliper of 0.05.^[@bibr26-1758835919833863]^ We compared the categorical variables in different groups using the Chi-square test or Fisher's exact test if indicated. The criterion for statistical significance was set at an α of 0.05 and all *p* values were based on two-sided tests. All statistical models were generated using R statistical software, version 3.3.2 (<http://www.r-project.org/>).

Results {#section12-1758835919833863}
=======

Patient characteristics and treatment outcomes {#section13-1758835919833863}
----------------------------------------------

The overall median age was 45 years (range, 18--81 years), and the male:female ratio was 3.1:1 (2337 men and 752 women). As is typical of endemic areas, histological examination revealed that 3019 (98%) patients had World Health Organization (WHO) type III disease, which is nonkeratinizing undifferentiated NPC. [Table 1](#table1-1758835919833863){ref-type="table"} shows the detailed clinicopathologic characteristics. The percentages of patients grouped as stage N2 and stage N3 were 64% and 36%, respectively. Most patients underwent IC followed by CCRT (57.7%) or CCRT alone (27.5%), 10.4% underwent IC plus RT, 2.1% underwent CCRT plus AC, and 2.3% were treated with IMRT alone. Furthermore, the number of patients with different induction, adjuvant and concurrent chemotherapy regimens are listed in [Table S1](https://journals.sagepub.com/doi/suppl/10.1177/1758835919833863). Following a median patient follow-up time of 51.2 months (range, 3.4--101.9 months), 592 (19.2%) developed distant metastases, and 533 (17.3%) died during the study period. Overall, the 3-year and 5-year DMFS, and 3-year and 5-year OS rates were 81.8% and 78.1%, and 87.4% and 76.7%, respectively.

###### 

Clinicopathologic characteristics and univariate analysis of DMFS and OS in the 3089 patients with advanced N-stage NPC.

![](10.1177_1758835919833863-table1)

  Characteristic                                                            Entire cohort no. (%)^[a](#table-fn2-1758835919833863){ref-type="table-fn"}^   Univariate analysis                                 
  ------------------------------------------------------------------------- ------------------------------------------------------------------------------ --------------------- --------- ------------------- ---------
  Sex                                                                                                                                                      HR (95% CI)           *p*       HR (95% CI)         *p*
   Male                                                                     2337 (75.7)                                                                    Reference                       Reference           
   Female                                                                   752 (24.3)                                                                     0.72 (0.59, 0.89)     0.002     0.84 (0.68, 1.03)   0.096
  Histology (WHO)                                                                                                                                                                                              
   Type I--II                                                               70(2.3)                                                                        Reference                       Reference           
   Type III                                                                 3019 (97.7)                                                                    0.69 (0.44, 1.09)     0.109     0.72 (0.46, 1.12)   0.143
  Age, years                                                                                                                                                                                                   
   ⩽30                                                                      354 (11.5)                                                                     Reference                       Reference           
   31--40                                                                   761 (24.6)                                                                     1.19 (0.87, 1.63)     0.274     1.15 (0.80, 1.63)   0.412
   41--50                                                                   1020 (33.0)                                                                    1.41 (1.04, 1.91)     0.014     1.43 (1.03, 1.99)   0.012
   51--60                                                                   652 (21.1)                                                                     1.28 (0.93, 1.77)     0.067     1.65 (1.17, 2.34)   0.006
   ⩾61                                                                      302 (9.8)                                                                      1.57 (1.10, 2.25)     0.070     2.19 (1.51, 3.19)   \<0.001
  Smoking history                                                                                                                                                                                              
   No                                                                       1877 (60.8)                                                                    Reference                       Reference           
   Yes                                                                      1212 (39.2)                                                                    1.24 (1.05, 1.46)     0.010     1.08 (0.91, 1.28)   0.394
  Family of cancer                                                                                                                                                                                             
   No                                                                       2335 (75.6)                                                                    Reference                       Reference           
   Yes                                                                      754 (24.4)                                                                     1.10 (0.91, 1.32)     0.327     1.03 (0.84, 1.25)   0.793
  T-stage (8th edition)                                                                                                                                                                                        
   T1                                                                       358 (11.6)                                                                     Reference                       Reference           
   T2                                                                       516 (16.7)                                                                     1.26 (0.88, 1.81)     0.475     1.34 (0.91, 1.96)   0.341
   T3                                                                       1523 (49.3)                                                                    1.64 (1.20, 2.24)     0.016     1.66 (1.19, 2.30)   0.021
   T4                                                                       692 (22.4)                                                                     1.97 (1.42, 2.73)     \<0.001   2.07 (1.46, 2.93)   \<0.001
  N-stage (8th edition)                                                                                                                                                                                        
   N2                                                                       1981(64.1)                                                                     Reference                       Reference           
   N3                                                                       1108 (35.9)                                                                    1.64 (1.39, 1.92)     \<0.001   1.64 (1.39, 1.95)   \<0.001
  EBV DNA, copy/ml^[b](#table-fn3-1758835919833863){ref-type="table-fn"}^                                                                                                                                      
   \<1000                                                                   759 (24.6)                                                                     Reference                       Reference           
   1000--9999                                                               807 (26.1)                                                                     1.78 (1.34, 2.36)     \<0.001   1.77 (1.31, 2.39)   \<0.001
   10,000--99,999                                                           992 (32.1)                                                                     2.36 (1.82, 3.07)     \<0.001   2.34 (1.78, 3.09)   \<0.001
   ⩾100,000                                                                 531 (17.2)                                                                     3.41 (2.59, 4.47)     \<0.001   3.07 (2.30, 4.10)   \<0.001
  HGB, g/l^[b](#table-fn3-1758835919833863){ref-type="table-fn"}^                                                                                                                                              
   \<113                                                                    122 (3.9)                                                                      Reference                       Reference           
   113--151                                                                 2037 (65.9)                                                                    0.57 (0.41, 0.79)     0.004     0.65 (0.45, 0.93)   0.012
   ⩾151                                                                     930 (30.1)                                                                     0.56 (0.39, 0.79)     0.001     0.55 (0.38, 0.81)   0.001
  hs-CRP, g/ml^[b](#table-fn3-1758835919833863){ref-type="table-fn"}^                                                                                                                                          
   \<1.0                                                                    824 (26.7)                                                                     Reference                       Reference           
   1.0--3.0                                                                 1124 (36.4)                                                                    1.14 (0.91, 1.42)     0.219     1.27 (1.00, 1.61)   0.049
   ⩾3.0                                                                     1141 (36.9)                                                                    1.56 (1.26, 1.93)     \<0.001   1.69 (1.35, 2.12)   \<0.001
  LDH, U/l^[b](#table-fn3-1758835919833863){ref-type="table-fn"}^                                                                                                                                              
   \<245                                                                    2713 (87.8)                                                                    Reference                       Reference           
   ⩾245                                                                     376 (12.2)                                                                     1.94 (1.58, 2.38)     \<0.001   1.80 (1.45, 2.24)   \<0.001

CI, confidence interval; DMFS, distant metastasis-free survival; EBV, Epstein--Barr virus; HGB, hemoglobin; HR, hazard ratio; hs-CRP, high-sensitivity C-reactive protein; LDH, lactate dehydrogenase; NPC, nasopharyngeal carcinoma; OS, overall survival; WHO, World Health Organization.

Percentages may not add up to 100, due to rounding.

All variables were measured before treatment.

The development of nomograms for DMFS and OS {#section14-1758835919833863}
--------------------------------------------

[Table 1](#table1-1758835919833863){ref-type="table"} presents the univariate analyses results. In multivariate analysis, sex, T stage, N-stage, EBV DNA, HGB, and LDH had proven significant effects on DMFS \[[Figure 1(a)](#fig1-1758835919833863){ref-type="fig"}\]; and age, T stage, N-stage, EBV DNA, HGB, hs-CRP, and LDH were significantly associated with OS \[[Figure 1(b)](#fig1-1758835919833863){ref-type="fig"}\]. Prognostic nomograms combining all aforementioned validated predictors for 3- and 5-year DMFS and OS are presented in [Figure 2(a)](#fig2-1758835919833863){ref-type="fig"} and ([b](#fig2-1758835919833863){ref-type="fig"}). The prognostic nomograms provided good accuracy for predicting DMFS and OS, with corresponding c-index values of 0.69 (95% CI, 0.64--0.73) and 0.71 (95% CI, 0.66--0.75), respectively. Moreover, calibration plots for the probabilities of 3- and 5-year DMFS \[[Figure 2(c)](#fig2-1758835919833863){ref-type="fig"} and ([e](#fig2-1758835919833863){ref-type="fig"})\] and OS \[[Figure 2(d)](#fig2-1758835919833863){ref-type="fig"} and ([f](#fig2-1758835919833863){ref-type="fig"})\] showed ideal agreement with the nomogram predictions for DMFS \[[Figure 2(a)](#fig2-1758835919833863){ref-type="fig"}\] and OS \[[Figure 2(b)](#fig2-1758835919833863){ref-type="fig"}\], respectively.

![Forest plots depicting the multivariate association of clinicopathological characteristics with distant metastasis-free survival (a) and overall survival (b).\
CI, confidence interval; EBV, Epstein--Barr virus; HGB, hemoglobin; HR, hazard ratio; hs-CRP, high-sensitivity C-reactive protein; LDH, lactate dehydrogenase.](10.1177_1758835919833863-fig1){#fig1-1758835919833863}

![Prognostic nomograms (a, b) and calibration plots of survival probabilities at 3 years (c, d) and 5 years (e, f) in patients with NPC. The left panel represents the nomogram and calibration plots for distant metastasis-free survival (a, c, e); the right panel represents the nomogram and calibration plots for overall survival (b, d, f).\
EBV, Epstein--Barr virus; HGB, hemoglobin; hs-CRP, high-sensitivity C-reactive protein; LDH, lactate dehydrogenase; NPC, nasopharyngeal carcinoma.](10.1177_1758835919833863-fig2){#fig2-1758835919833863}

Nomogram-generated risk stratification for distant metastasis {#section15-1758835919833863}
-------------------------------------------------------------

Based on the total score of nomograms for distant metastasis, all patients were categorized into risk groups: low-risk group (582 patients; total score ⩽ 150 points); intermediate-risk group (1791 patients; 150 \< total score ⩽ 300 points); and high-risk group (716 patients; total score \> 300 points). [Supplementary Tables S2](https://journals.sagepub.com/doi/suppl/10.1177/1758835919833863) and [S3](https://journals.sagepub.com/doi/suppl/10.1177/1758835919833863) present the objective hematological toxicities and liver and kidney dysfunction of each risk group before and during treatment, respectively. Survival curves showed excellent discrimination in distant failure among the low-risk group, intermediate-risk group, and high-risk group, with corresponding 5-year DMFS rates of 90.7%, 79.4%, and 64.9%, respectively \[*p* \< 0.001; [Figure 3(a)](#fig3-1758835919833863){ref-type="fig"}\]. In addition, the 5-year OS rates for the low-risk group (89.9%), intermediate-risk group (77.7%), and high-risk group (64.9%) also differed significantly between groups \[*p* \< 0.001; [Figure 3(b)](#fig3-1758835919833863){ref-type="fig"}\].

![Kaplan--Meier survival curves are shown for (a) distant metastasis-free survival and overall survival (b) in patients with advanced N-stage NPC stratified by the total score of nomograms. Low-risk group: total score ⩽ 150 points; intermediate-risk group: 150 \< total score ⩽ 300 points; high-risk group: total score \> 300 points.\
NPC, nasopharyngeal carcinoma.](10.1177_1758835919833863-fig3){#fig3-1758835919833863}

Benefits of adding IC to CCRT in each risk group {#section16-1758835919833863}
------------------------------------------------

The nomogram-generated stratification based on DMFS showed patients that had an advanced N-stage receiving IC plus CCRT or CCRT alone were categorized into a low-risk group, intermediate-risk group, or high-risk group, with a total of 603, 1530, and 499 patients in each group, respectively. Based on the results of DMFS in multivariate analysis, all aforementioned validated predictors (sex, T-stage, N-stage, EBV DNA, HGB, and LDH) were selected for inclusion in the propensity score analysis in the methods section. Moreover, as serum hs-CRP has been confirmed to be an important factor of distant metastasis,^[@bibr27-1758835919833863][@bibr28-1758835919833863][@bibr29-1758835919833863]--[@bibr30-1758835919833863]^ it was also incorporated into the propensity score analysis. The baseline characteristics of patients receiving either IC plus CCRT or CCRT alone were unbalanced ([Table 2](#table2-1758835919833863){ref-type="table"}). Compared with the low and intermediate-risk groups, the high-risk group generally had more male patients, staged with T3--4 stage, N3 stage and IV stage disease, elevated EBV DNA, hs-CRP and LDH levels, and receiving the treatment of IC plus CCRT (*p* \< 0.001 for all). Using the PSM method, three well-matched risk groups were created to compare IC plus CCRT with CCRT alone for each risk group (all *p* \> 0.05). The detailed baseline characteristics for all risk groups are presented in [Table 3](#table3-1758835919833863){ref-type="table"}. In addition, [Supplementary Table S4](https://journals.sagepub.com/doi/suppl/10.1177/1758835919833863) shows the number of patients with different induction, adjuvant and concurrent chemotherapy regimens for each risk group after PSM.

###### 

The baseline characteristics of high, intermediate, and low-risk groups in patients treated with IC plus CCRT or CCRT alone before propensity score matching.

![](10.1177_1758835919833863-table2)

  Characteristic                                                            High-risk group (*n* = 603)   Intermediate-risk group (*n* = 1530)   Low-risk group (*n* = 499)   *p* value
  ------------------------------------------------------------------------- ----------------------------- -------------------------------------- ---------------------------- -----------
  Sex                                                                                                                                                                         \<0.001
   Male                                                                     524 (86.9)                    1192 (77.9)                            279 (55.9)                   
   Female                                                                   79 (13.1)                     338 (22.1)                             220 (44.1)                   
  Histology (WHO)                                                                                                                                                             0.018
   Type I--II                                                               13 (2.2)                      44 (2.9)                               4 (0.8)                      
   Type III                                                                 590 (97.8)                    1486 (97.1)                            495 (99.2)                   
  Age, years                                                                                                                                                                  0.002
   ⩽30                                                                      85 (14.1)                     172 (11.2)                             53 (10.6)                    
   31--40                                                                   148 (24.5)                    382 (25.0)                             159 (31.9)                   
   41--50                                                                   202 (33.5)                    527 (34.4)                             156 (31.3)                   
   51--60                                                                   117 (19.4)                    320 (20.9)                             111 (22.2)                   
   ⩾61                                                                      51 (8.5)                      129 (8.4)                              20 (4.0)                     
  Smoking history                                                                                                                                                             0.018
   No                                                                       336 (55.7)                    885 (57.8)                             362 (72.5)                   
   Yes                                                                      267 (44.3)                    645 (42.2)                             137 (27.5)                   
  Family of cancer                                                                                                                                                            0.296
   No                                                                       463 (76.8)                    1162 (75.9)                            364 (72.9)                   
   Yes                                                                      140 (23.2)                    368 (24.1)                             135 (27.1)                   
  T-stage (8th edition)                                                                                                                                                       \<0.001
   T1                                                                       19 (3.2)                      149 (9.7)                              137 (27.5)                   
   T2                                                                       48 (8.0)                      264 (17.3)                             122 (24.4)                   
   T3                                                                       338 (56.1)                    746 (48.8)                             217 (43.5)                   
   T4                                                                       198 (32.8)                    371 (24.2)                             23 (4.6)                     
  N-stage (8th edition)                                                                                                                                                       \<0.001
   N2                                                                       176 (29.2)                    1049 (68.6)                            448 (89.8)                   
   N3                                                                       427 (70.8)                    481 (31.4)                             51 (10.2)                    
  Overall stage (8th edition)                                                                                                                                                 \<0.001
   III                                                                      95 (15.8)                     743 (48.6)                             431 (86.4)                   
   IV                                                                       508 (84.2)                    787 (51.4)                             51 (10.2)                    
  EBV DNA, copy/ml^[b](#table-fn6-1758835919833863){ref-type="table-fn"}^                                                                                                     \<0.001
   \<1000                                                                   0 (0)                         243 (15.9)                             416 (83.4)                   
   1000--9999                                                               51 (8.5)                      591 (38.6)                             57 (11.4)                    
   10,000--99,999                                                           243 (40.3)                    569 (37.2)                             26 (5.2)                     
   ⩾100,000                                                                 309 (51.2)                    127 (8.3)                              0 (0)                        
  HGB, g/l^[b](#table-fn6-1758835919833863){ref-type="table-fn"}^                                                                                                             \<0.001
   \<113                                                                    58 (9.6)                      45 (2.9)                               2 (0.4)                      
   113--151                                                                 374 (62.0)                    1001 (65.4)                            351 (70.3)                   
   ⩾151                                                                     171 (28.4)                    484 (31.6)                             146 (29.3)                   
  hs-CRP, g/ml^[b](#table-fn6-1758835919833863){ref-type="table-fn"}^                                                                                                         \<0.001
   \<1.0                                                                    90 (14.9)                     417 (27.3)                             215 (43.1)                   
   1.0--3.0                                                                 164 (27.2)                    559 (36.5)                             219 (43.9)                   
   ⩾3.0                                                                     349 (57.9)                    554 (36.2)                             65 (13.0)                    
  LDH, U/l^[b](#table-fn6-1758835919833863){ref-type="table-fn"}^                                                                                                             \<0.001
   \<245                                                                    367 (60.9)                    1457 (95.2)                            493 (98.8)                   
   ⩾245                                                                     235 (39.0)                    73 (4.8)                               6 (1.2)                      
  Treatment                                                                                                                                                                   \<0.001
   IC plus CCRT                                                             484 (80.3)                    1027 (67.1)                            272 (54.5)                   
   CCRT alone                                                               119 (19.7)                    503 (32.9)                             227 (45.5)                   

CCRT, concurrent chemoradiotherapy; EBV, Epstein--Barr virus; HGB, hemoglobin; hs-CRP, high-sensitivity C-reactive protein; IC, induction chemotherapy; LDH, lactate dehydrogenase; NPC, nasopharyngeal carcinoma; WHO, World Health Organization.

Percentages may not add up to 100, due to rounding.

All variables were measured before treatment.

###### 

The baseline characteristics of the patients treated with IC plus CCRT or CCRT alone in each risk group based on the propensity score matching method.

![](10.1177_1758835919833863-table3)

  Characteristic                                                            High-risk group   Intermediate-risk group   Low-risk group                                                               
  ------------------------------------------------------------------------- ----------------- ------------------------- ---------------- ------------ ------------ ------- ------------ ------------ -------
  Sex                                                                                                                   0.599                                      0.657                             0.275
   Male                                                                     14 (13.7)         35 (11.5)                                  88 (19.6)    161 (18.6)           81 (39.9)    80 (34.8)    
   Female                                                                   88 (86.3)         269 (88.5)                                 361 (80.4)   706 (81.4)           122 (60.1)   150 (65.2)   
  T-stage (8th edition)                                                                                                 0.571                                      0.093                             0.266
   T1                                                                       1 (1.0)           2 (0.7)                                    48 (10.7)    64 (7.4)             53 (26.1)    52 (22.6)    
   T2                                                                       5 (4.9)           10 (3.3)                                   75 (16.7)    146 (16.8)           57 (28.1)    52 (22.6)    
   T3                                                                       72 (70.6)         206 (67.8)                                 246 (54.8)   466 (53.7)           92 (45.3)    123 (53.5)   
   T4                                                                       24 (23.5)         86 (28.3)                                  80 (17.8)    191 (22.0)           1 (0.5)      3 (1.3)      
  N-stage (8th edition)                                                                                                 0.316                                      0.612                             0.862
   N2                                                                       34 (33.3)         85 (28.0)                                  319 (71.0)   604 (69.7)           187 (92.1)   210 (91.3)   
   N3                                                                       68 (66.7)         219 (72.0)                                 130 (29.0)   263 (30.3)           16 (7.9)     20 (8.7)     
  EBV DNA, copy/ml^[b](#table-fn9-1758835919833863){ref-type="table-fn"}^                                               0.758                                      0.939                             0.956
   \<1000                                                                   0 (0)             0 (0)                                      60 (13.4)    117 (13.5)           170 (83.7)   195 (84.8)   
   1000--9999                                                               6 (5.9)           16 (5.3)                                   190 (42.3)   352 (40.6)           25 (12.3)    26 (11.3)    
   10,000--99,999                                                           46 (45.1)         150 (49.3)                                 169 (37.6)   340 (39.2)           8 (3.9)      9 (3.9)      
   ⩾100,000                                                                 50 (49.0)         138 (45.4)                                 30 (6.7)     58 (6.7)             0 (0)        0 (0)        
  HGB, g/l^[b](#table-fn9-1758835919833863){ref-type="table-fn"}^                                                       0.249                                      0.597                             0.051
   \<113                                                                    5 (4.9)           7 (2.3)                                    6 (1.3)      7 (0.7)              0 (0)        0 (0)        
   113--151                                                                 73 (71.6)         209 (68.8)                                 298 (66.4)   585 (67.5)           147 (72.4)   146 (63.5)   
   ⩾151                                                                     24 (23.5)         88 (28.9)                                  145 (32.3)   276 (31.8)           56 (27.6)    84 (36.5)    
  hs-CRP, g/ml^[b](#table-fn9-1758835919833863){ref-type="table-fn"}^                                                   0.906                                      0.722                             0.661
   \<1.0                                                                    14 (13.7)         42 (13.8)                                  118 (26.3)   217 (25.0)           87 (42.9)    93 (40.4)    
   1.0--3.0                                                                 25 (24.5)         81 (26.6)                                  163 (36.3)   334 (38.5)           93 (45.8)    115 (50.0)   
   ⩾3.0                                                                     63 (61.8)         181 (59.5)                                 168 (37.4)   316 (36.4)           23 (11.3)    22 (9.6)     
  LDH, U/l^[b](#table-fn9-1758835919833863){ref-type="table-fn"}^                                                       0.085                                      0.487                             0.999
   \<245                                                                    63 (61.8)         216 (71.1)                                 440 (98.0)   855 (98.6)           203 (100)    230 (100)    
   ⩾245                                                                     39 (38.2)         88 (28.9)                                  9 (2.0)      12 (1.4)             0 (0)        0 (0)        

CCRT, concurrent chemoradiotherapy; EBV, Epstein--Barr virus; HGB, hemoglobin; hs-CRP, high-sensitivity C-reactive protein; IC, induction chemotherapy; LDH, lactate dehydrogenase; NPC, nasopharyngeal carcinoma.

Percentages may not add up to 100, due to rounding.

All variables were measured before treatment.

[Figure 3](#fig3-1758835919833863){ref-type="fig"} presents all direct comparisons between IC plus CCRT and CCRT alone for each risk group through the PSM method. In the high-risk group, IC plus CCRT revealed a significant improvement for DMFS compared with CCRT alone \[5-year DMFS, 69.5% *versus* 56.7%, *p* = 0.004; [Figure 4(a)](#fig4-1758835919833863){ref-type="fig"}\]. In the intermediate-risk group, no significant difference was observed between IC plus CCRT and CCRT alone \[*p* = 0.831; [Figure 4(b)](#fig4-1758835919833863){ref-type="fig"}\]. Additionally, IC plus CCRT tended to improve DMFS in the first 3 years after treatment compared with CCRT alone (3-year DMFS, 84.5% *versus* 83.2%), however this trend changed at year 5 (5-year DMFS, 79.8% *versus* 81.1%). In the low-risk group, patients who were treated with IC plus CCRT did not show an improvement benefit for DMFS compared with those treated with CCRT alone (*p* = 0.608). In contrast, IC plus CCRT tended to display an unfavorable DMFS in comparison with CCRT alone \[3-year DMFS, 93.5% *versus* 97.0%; [Figure 4(c)](#fig4-1758835919833863){ref-type="fig"}\].

![Kaplan--Meier curves of distant metastasis-free survival for the high-risk group (a), intermediate-risk group (b), and low-risk group (c) with IC plus CCRT or CCRT alone.\
IC, induction chemotherapy; CCRT, concurrent chemoradiotherapy.](10.1177_1758835919833863-fig4){#fig4-1758835919833863}

Discussion {#section17-1758835919833863}
==========

In the current study, a prognostic nomogram based on EBV DNA, TNM staging system, and hematology and biochemistry profiling in comparison with clinical risk factors improves the ability to predict DMFS in advanced N-stage NPC patients. Our results revealed the nomograms of DMFS developed in this study categorizing patients into low, intermediate, and high-risk groups for significantly different DMFS rates. Moreover, we showed that IC plus CCRT *versus* CCRT alone provided improved survival benefit among high-risk patients through the PSM method, but not in those classified in the intermediate-risk and low-risk groups.

Cancer is a heterogeneous disease. In addition to the anatomical extent of NPC, classic tumor-related prognostic factors, such as EBV DNA,^[@bibr31-1758835919833863]^ HGB,^[@bibr32-1758835919833863]^ hs-CRP,^[@bibr27-1758835919833863],[@bibr28-1758835919833863]^ and LDH,^[@bibr20-1758835919833863]^ were reported to independently correlate with treatment outcomes. Among these factors, we found EBV DNA was the most related prognostic factor for predicting distant failure. In fact, EBV infection is an important causative factor for NPC in endemic regions. Additionally, inherent genetic heterogeneity of NPC patients suggests inter-individual variations in EBV infection susceptibility, and EBV's ability to prompt malignant transformation.^[@bibr33-1758835919833863]^ Additionally, Lo and colleagues^[@bibr34-1758835919833863]^ found that for every 10-fold rise in plasma EBV DNA level to predict clinical events, the relative risk was 3.8 (95% CI, 1.6--9.2). For this reason, EBV DNA is potentially the ideal biomarker to complement the current TNM stage in the future.

To predict the risk of distant metastasis, we built a nomogram in the current study. Though such methods largely rely on traditional prognostic factors, such as T-stage and N-stage which reflects the anatomical information of tumors. We suggest that plasma EBV DNA reflects the tumor heterogeneity,^[@bibr35-1758835919833863]^ whereas blood parameters (e.g. hs-CRP and LDH) provide greater insights into the systemic inflammatory status of patients, and the increased concentrations of these are related to inferior NPC survival.^[@bibr20-1758835919833863],[@bibr27-1758835919833863]^ To support this, our results indicated that the established nomograms including the anatomical information of tumors, EBV DNA, and blood parameters, predicted treatment outcomes with good accuracy. Moreover, patients grouped by high, intermediate, and low-risk groups categorized by the nomograms provided excellent discrimination in distant metastasis. Hence, our nomograms might provide a simple and precise method of predicting distant failure in advanced N-stage NPC.

In this study, the individualized risk stratification of nomograms was applied to identify subgroups where it would be advantageous for the addition of IC to CCRT to improve survival. Our results confirmed that IC for high-risk patients was advantageous for improving distant control but this was not observed in those classified as low-risk patients, despite the balanced characteristics between the two arms. The most likely reason for IC benefiting high-risk patients only in the present study is the result of bulky or extensive nodal disease, which has an elevated risk for distant metastasis.^[@bibr13-1758835919833863]^ Another explanation for the lower efficacy of IC in the low-risk patient group might have been the delay of RT start time for patients receiving IC before CCRT, resulting in a sub-additive effect. Although there was no difference in survival between IC and CCRT together *versus* CCRT alone for the intermediate-risk patients, IC plus CCRT achieved a higher DMFS rate than CCRT alone in the first 3 years after treatment, while this trend reversed at 5 years. Therefore, it is difficult to determine which treatment strategy is more appropriate for this group of patients, and clinical trials should be considered in this subgroup in the future.

A main strength in the present study was the head-to-head comparison among patients given CCRT with or without IC through risk stratification of nomograms and the PSM method in each group. This addressed both divergent confounders and the selection bias associated with observational data retrospective analysis.^[@bibr36-1758835919833863]^ Another strength was the large-scale data derived from real-world medical records, which reflect the actual medical treatment process and the patient's health under real conditions. Nevertheless, there are some limitations that must be noted. First, although these nomograms presented excellent agreement between calibration plots and satisfactory c-indexes, external validation was not performed due to a deficiency in the available per-patient data from other hospitals within the endemic area. For this reason, the generalizability of the results to other patient populations is not certain. Another limitation was the heterogeneity of the IC regimen and dosage because of the retrospective study design. Finally, since the intelligence platform of our center failed to collect the data on acute and late toxicities, treatment-related toxicities were lacking in the current study.

In conclusion, we developed a nomogram to predict DMFS rates for advanced N-stage NPC patients in the endemic area, which provided an improved ability to predict DMFS. The low, intermediate, or high-risk groups categorized by the proposed nomograms presented excellent discrimination in DMFS rates. Although the addition of IC to CCRT provided survival benefits for high-risk patients, it failed to retain benefits in those classified as intermediate and low-risk patients. Considering the potential morbidity, cost, and inconvenience of IC, the intermediate and low-risk groups may prefer to avoid IC, given the relatively small expected benefit. The present study can serve as a catalyst for treatment discussions and facilitate informed decision-making.
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